title: The SGLT2 Inhibitor Empagliflozin for the Treatment of Type 2 Diabetes Mellitus: a Bench to Bedside Review.
abstract: BACKGROUND
  The treatment of type 2 diabetes mellitus (T2DM) continues to pose challenges for clinicians and patients. The dramatic rise in T2DM prevalence, which has paralleled the rise in obesity, has strained the healthcare system and prompted the search for therapies that not only effectively treat hyperglycemia, but are also weight neutral or promote weight loss. In most clinical situations after diagnosis, patients are advised to adopt lifestyle changes and metformin is initiated to help control blood glucose levels. However, metformin may not be tolerated, or may not be sufficient for those with higher glucose levels at diagnosis. Even among those who have initial success with metformin, the majority eventually require one or more additional agents to achieve their treatment goals. Because T2DM is a progressive disease, the requirement for combination treatment escalates over time, driving the need for therapies with complementary mechanisms of action.
  
  
  RESULTS
  Online public resources were searched using "empagliflozin", identifying 32 articles in PubMed, and 12 abstracts presented at the 2013 American Diabetes Association meeting. Peer-reviewed articles and abstracts describing preclinical studies and clinical trials were retrieved, and relevant publications included in this review. Trials registered on clinicaltrials.gov were searched for ongoing empagliflozin studies.
  
  
  CONCLUSIONS
  The sodium-glucose co-transporter 2 (SGLT2) inhibitors are of great interest since they provide a novel, insulin-independent mechanism of action. The SGLT2 inhibitor empagliflozin has demonstrated promising pharmacodynamic and pharmacokinetic properties. In clinical trials, empagliflozin has demonstrated a good efficacy and safety profile in a broad range of patients with T2DM, and appears to be an attractive adjunct therapeutic option for the treatment of T2DM. Ongoing trials, including patients with T2DM and comorbidities such as hypertension, are expected to provide important additional data, which will further define the role of empagliflozin in a growing movement toward individualized approaches to diabetes care.
authors.affiliation: Division of Endocrinology, Metabolism and Lipid Research, Washington University School of Medicine, 660 S. Euclid, Campus Box 8127, St. Louis, MO, 63110, USA, JMCGILL@DOM.wustl.edu.
authors.forename: Janet B
authors.initials: JB
authors.lastname: McGill
references.citation: Biochem J. 1967 Sep;104(3):852-60
references.pmid: 6049927
references.citation: J Clin Invest. 2014 Feb;124(2):499-508
references.pmid: 24463454
references.citation: J Clin Endocrinol Metab. 2010 Jan;95(1):34-42
references.pmid: 19892839
references.citation: Endocr Rev. 2011 Aug;32(4):515-31
references.pmid: 21606218
references.citation: Diabetes Obes Metab. 2013 Apr;15(4):316-23
references.pmid: 23094794
references.citation: Drug Metab Pharmacokinet. 2013;28(3):213-9
references.pmid: 23149871
references.citation: J Clin Invest. 2014 Feb;124(2):509-14
references.pmid: 24463448
references.citation: Endocr Pract. 2013 Mar-Apr;19(2):327-36
references.pmid: 23598536
references.citation: Cardiovasc Diabetol. 2013 Apr 24;12:70
references.pmid: 23617452
references.citation: Diabetes Obes Metab. 2014 Mar;16(3):215-22
references.pmid: 23859488
references.citation: Diabetes Obes Metab. 2012 Jan;14(1):94-6
references.pmid: 21985693
references.citation: Clin Pharmacol Ther. 2012 Aug;92(2):158-69
references.pmid: 22739142
references.citation: Diabetes Obes Metab. 2013 Jul;15(7):613-21
references.pmid: 23356556
references.citation: Lancet Diabetes Endocrinol. 2013 Nov;1(3):208-19
references.pmid: 24622369
references.citation: Diabetes Metab Res Rev. 2005 Jan-Feb;21(1):31-8
references.pmid: 15624123
references.citation: J Clin Invest. 1987 May;79(5):1510-5
references.pmid: 3571496
references.citation: J Clin Endocrinol Metab. 2012 Dec;97(12):4293-301
references.pmid: 23185035
references.citation: Diabetes Ther. 2013 Dec;4(2):331-45
references.pmid: 23838841
references.citation: Cardiovasc Diabetol. 2013 Sep 05;12:129
references.pmid: 24007456
references.citation: Br J Clin Pharmacol. 2010 Jul;70(1):16-23
references.pmid: 20642543
references.citation: Diabetes Care. 2013 Sep;36(9):2690-6
references.pmid: 23637354
references.citation: Diabetes Care. 2013 Apr;36(4):1033-46
references.pmid: 23468086
references.citation: Diabetes Obes Metab. 2014 Feb;16(2):147-58
references.pmid: 23906415
references.citation: Adv Ther. 2012 Oct;29(10):889-99
references.pmid: 23054692
references.citation: Diabetes Care. 2013 Nov;36(11):3396-404
references.pmid: 23963895
references.citation: Int J Clin Pharmacol Ther. 2013 Feb;51(2):132-40
references.pmid: 23253948
references.citation: Clin Drug Investig. 2013 May;33(5):351-7
references.pmid: 23512637
references.citation: Diabetes Obes Metab. 2013 Aug;15(8):721-8
references.pmid: 23398530
references.citation: Biochim Biophys Acta. 1962 Jan 1;56:170-2
references.pmid: 13860792
references.citation: Diabetes Obes Metab. 2013 Dec;15(12):1154-60
references.pmid: 23906374
references.citation: Clin Pharmacol Drug Dev. 2013 Apr;2(2):152-61
references.pmid: 27121669
references.citation: Diabetes Obes Metab. 2012 Jan;14(1):83-90
references.pmid: 21985634
references.citation: Diabetes Obes Metab. 2014 Feb;16(2):118-23
references.pmid: 23859534
references.citation: Clin Ther. 2013 Mar;35(3):226-35
references.pmid: 23497760
references.citation: Diabetes Care. 2014 Jan;37 Suppl 1:S14-80
references.pmid: 24357209